世衛若沒提供科興疫苗的評估報告, 老韭們大概只能寄望中國藥廠生產的俄羅斯疫苗了~
"The Russian Direct Investment Fund, which has been in charge of international cooperation for Sputnik V, said in April it would produce 100 million doses in collaboration with Hualan Biological Bacterin Inc., in addition to an earlier deal announced in March for 60 million doses with Shenzhen Yuanxin Gene tech Co.
The two deals are in addition to a deal announced last November with Tibet Rhodiola Pharmaceutical Holding Co, which had paid $9 million to manufacture and sell the Sputnik V vaccine in China. RDIF said in April the terms of the deal were for 100 million doses with a subsidiary company belonging to Tibet Rhodiola."
"However, none of the three Chinese companies has begun manufacturing Sputnik V as of yet."
結果親中的新加坡宣布打科興疫苗者不計入疫苗接種人數內....
"Both have shown efficacy rates of well over 90% against symptomatic disease in clinical trials, compared with trials for Sinovac that shown results from as low as 51% to about 84%."
泰國這研究等於是說打科興者在兩個月後回到接種前⋯
「曼谷郵報（Bangkok Post）報導，這份研究是由泰國法政大學（Thammasat University）以及國家基因工程與生物技術中心（National Centre for Genetic Engineering and Biotechnology ）共同完成。
這份研究由國家基因工程與生物技術中心轄下的研究團隊主任安南（Anan Jongkaewwattan）在臉書上公布結果。
安南指出，他們研究了500個接受2劑科興疫苗的民眾，發現每40天民眾體內的抗體就減少50%，第一劑和第二劑間隔超過60天的人，抗體會低於第一劑和第二劑間隔在60天以內的人。」
各家疫苗對變異株的防護效果會是下半年的評估重點:
"Sinovac and Sinopharm are studying the protection the vaccines provide against the Delta variant, but haven’t released any data yet. Both companies have said a booster shot may be needed at some point after their two-dose regimens.
Two recent studies in the U.K. determined that vaccines made by Pfizer and AstraZeneca are highly effective at preventing severe illness caused by the variant, while their overall protection against infection may be reduced. A separate study of the Pfizer vaccine conducted in Israel showed similar outcomes."
